Wockhardt Ltd
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
- Market Cap ₹ 5,027 Cr.
- Current Price ₹ 349
- High / Low ₹ 365 / 145
- Stock P/E
- Book Value ₹ 217
- Dividend Yield 0.00 %
- ROCE -0.46 %
- ROE -8.31 %
- Face Value ₹ 5.00
Pros
- Company's working capital requirements have reduced from 79.0 days to 52.7 days
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.26%
- The company has delivered a poor sales growth of -7.60% over past five years.
- Company has a low return on equity of 4.21% over last 3 years.
- Promoters have pledged 64.4% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4,350 | 5,609 | 4,830 | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,774 | |
2,996 | 3,606 | 3,805 | 3,772 | 3,959 | 4,002 | 3,935 | 3,604 | 2,725 | 2,771 | 2,932 | 2,550 | 2,638 | |
Operating Profit | 1,355 | 2,004 | 1,026 | 709 | 494 | 13 | 2 | -38 | 119 | -63 | 298 | 101 | 136 |
OPM % | 31% | 36% | 21% | 16% | 11% | 0% | 0% | -1% | 4% | -2% | 9% | 4% | 5% |
-394 | 187 | 88 | 67 | 66 | 114 | -238 | 116 | 133 | 975 | -163 | -172 | -41 | |
Interest | 269 | 215 | 83 | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 314 |
Depreciation | 115 | 122 | 140 | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 232 |
Profit before tax | 577 | 1,853 | 891 | 575 | 289 | -247 | -641 | -351 | -247 | 417 | -411 | -624 | -451 |
Tax % | 41% | 14% | 5% | 28% | 13% | 9% | -4% | 38% | 82% | -65% | 32% | 0% | |
343 | 1,594 | 843 | 413 | 252 | -226 | -667 | -217 | -43 | 688 | -279 | -621 | -548 | |
EPS in Rs | 111.87 | 58.91 | 28.30 | 17.45 | -13.62 | -42.30 | -13.52 | -4.81 | 47.64 | -16.94 | -38.80 | -35.74 | |
Dividend Payout % | 0% | 3% | 13% | 54% | 0% | -56% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -7% |
5 Years: | -8% |
3 Years: | -2% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 3% |
3 Years: | % |
TTM: | -132% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | -5% |
3 Years: | -4% |
1 Year: | 51% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 1% |
3 Years: | 4% |
Last Year: | -8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 72 |
Reserves | 655 | 2,351 | 3,228 | 3,362 | 3,720 | 3,281 | 2,797 | 2,619 | 2,616 | 3,321 | 3,777 | 3,282 | 3,053 |
Preference Capital | 761 | 299 | 299 | 299 | 0 | 0 | 0 | 234 | 0 | 0 | 0 | 0 | |
3,281 | 2,070 | 1,906 | 2,010 | 2,677 | 4,160 | 3,748 | 3,141 | 3,582 | 2,674 | 2,198 | 2,184 | 2,274 | |
2,263 | 1,547 | 1,433 | 1,512 | 1,622 | 1,486 | 1,528 | 1,998 | 1,894 | 1,696 | 2,168 | 2,113 | 2,021 | |
Total Liabilities | 6,254 | 6,023 | 6,622 | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,746 | 8,215 | 7,651 | 7,420 |
2,571 | 1,990 | 2,295 | 2,123 | 2,809 | 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 4,117 | |
CWIP | 902 | 491 | 708 | 1,007 | 1,036 | 1,244 | 1,433 | 1,445 | 1,585 | 1,379 | 1,342 | 1,539 | 419 |
Investments | 91 | 3 | 577 | 341 | 0 | 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 |
2,689 | 3,539 | 3,043 | 3,468 | 4,228 | 4,403 | 3,593 | 3,309 | 3,060 | 3,024 | 3,411 | 3,070 | 2,884 | |
Total Assets | 6,254 | 6,023 | 6,622 | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,746 | 8,215 | 7,651 | 7,420 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,352 | 1,532 | 1,476 | 355 | -42 | -269 | 68 | 183 | 649 | -287 | 413 | 153 | |
-305 | 1,074 | -823 | -222 | -105 | -684 | 635 | 93 | -147 | 1,471 | -204 | -118 | |
-827 | -2,246 | -601 | -76 | 193 | 1,254 | -769 | -776 | -680 | -1,171 | -71 | -315 | |
Net Cash Flow | 220 | 360 | 52 | 57 | 46 | 301 | -66 | -500 | -178 | 13 | 138 | -280 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 64 | 62 | 36 | 60 | 91 | 94 | 89 | 130 | 159 | 124 | 104 | 110 |
Inventory Days | 211 | 221 | 201 | 250 | 249 | 243 | 174 | 183 | 209 | 256 | 222 | 216 |
Days Payable | 129 | 132 | 113 | 136 | 144 | 117 | 122 | 187 | 272 | 223 | 265 | 285 |
Cash Conversion Cycle | 146 | 151 | 124 | 175 | 196 | 220 | 141 | 126 | 97 | 157 | 60 | 41 |
Working Capital Days | 13 | 42 | 9 | 43 | 97 | 96 | -16 | 7 | -47 | 122 | 62 | 53 |
ROCE % | 29% | 42% | 18% | 10% | 7% | -1% | -1% | -1% | 0% | 12% | 1% | -0% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 22 Nov
- Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended 30Th September, 2023 14 Nov
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
14 Nov - Listing Regulations, please find enclosed Press Release on the Unaudited Financial Results(Standalone and Consolidated) for the quarter and half year ended 30th September, 2023.
- Board Meeting Outcome for Outcome Of The Board Meeting 14 Nov
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 9 Nov
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2023Transcript PPT
-
Mar 2022TranscriptNotesPPT
Market Position
The Co. is amongst top 3 Indian generic companies in the UK and 6th Largest generic supplier in Ireland in Retail and Hospital channels.
Its Wepox is the leader in Erythropoetin market (market share =21%)and Methylcobalamin Brand is no. 1 with (Methycobal= 26.7% market share) {#https://www.bseindia.com/bseplus/AnnualReport/532300/73832532300.pdf#page=34 #}